GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Karuna Therapeutics Inc (NAS:KRTX) » Definitions » Institutional Ownership

Karuna Therapeutics (Karuna Therapeutics) Institutional Ownership : 66.57% (As of Apr. 28, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Karuna Therapeutics Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Karuna Therapeutics's institutional ownership is 66.57%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Karuna Therapeutics's Insider Ownership is 0.83%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Karuna Therapeutics's Float Percentage Of Total Shares Outstanding is 95.72%.


Karuna Therapeutics Institutional Ownership Historical Data

The historical data trend for Karuna Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Karuna Therapeutics Institutional Ownership Chart

Karuna Therapeutics Historical Data

The historical data trend for Karuna Therapeutics can be seen below:

2023-05-31 2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29
Institutional Ownership 82.25 82.62 82.35 81.85 84.38 82.05 82.58 73.69 66.74 66.57

Karuna Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Karuna Therapeutics (Karuna Therapeutics) Business Description

Traded in Other Exchanges
Address
99 High Street, 26th Floor, Boston, MA, USA, 02110
Karuna Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by unmet medical needs. Its product candidate, KarXT is an oral modulator of muscarinic receptors that are located both in the central nervous system, or CNS, and various peripheral tissues.
Executives
Stephen K. Brannan officer: Chief Medical Officer C/O KARUNA THERAPEUTICS, INC., 33 ARCH STREET, SUITE 3110, BOSTON MA 02110
Jason Parker Brown officer: Chief Financial Officer KARUNA THERAPEUTICS, INC., 99 HIGH STREET, 26TH FLOOR, BOSTON MA 02110
Jeffrey M Jonas director ROBERTS SHERIDAN & KOTEL, 12 EAST 49TH STREET 30TH FL, NEW YORK NY 10017
Troy A. Ignelzi officer: Chief Financial Officer C/O ESPERION THERAPEUTICS, INC., 46701 COMMERCE CENTER DRIVE, PLYMOUTH MI 48170
Andrew Craig Miller officer: Chief Operating Officer C/O KARUNA THERAPEUTICS, INC., 33 ARCH STREET, SUITE 3110, BOSTON MA 02110
Laurie J Olson director C/O PFIZER INC. CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Kane William P Jr officer: Chief Commercial Officer C/O BIOXCEL THERAPEUTICS, INC., 555 LONG WHARF DRIVE, NEW HAVEN CT 06511
James Healy director 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
William Meury director, officer: President and CEO C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Atul Pande director C/O AXOVANT SCIENCES, INC., 1441 BROADWAY, 3RD FLOOR, NEW YORK NY 10018
Charmaine Lykins officer: Chief Commercial Officer C/O KARUNA THERAPEUTICS, INC., 99 HIGH STREET, 26TH FLOOR, BOSTON MA 02110
Steven M Paul director, officer: President & CEO C/O ELI LITTY & CO, LIIY CORPORATE CENTER DC 1093, INDIANAPOLIS IN 46285
Puretech Health Llc 10 percent owner 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Denice Torres director 3 RABBIT RUN DRIVE, NEW HOPE PA 18938
David E. Wheadon director C/O ASSERTIO THERAPEUTICS, INC., 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045

Karuna Therapeutics (Karuna Therapeutics) Headlines

From GuruFocus

Karuna Therapeutics to Present at Upcoming Investor Conferences

By Business Wire Business Wire 05-02-2023